CYP2S1 rs338599 polymorphism confers reduced risk to anti-tuberculosis drug-induced liver injury and may be a novel marker for its risk prediction.

PURPOSE

In the present study, we would like to explore whether Cytochrome P450 2S1 (CYP2S1) rs338599 polymorphism confers risk to anti-tuberculosis drug-induced liver injury (ADLI) and provide evidence of being used as novel marker for ADLI risk prediction.

PATIENTS AND METHODS

A total of 162 pulmonary tuberculosis patients admitted to Affiliated Hospital of Hebei University from August 2018 to March 2021 were selected. Patients who developed into ADLI were assigned as ADLI group (n = 50), and those who did not developed into ADLI were assigned as non-ADLI group (n = 112). The CYP2S1 rs338599 polymorphism was detected by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method using binary logistic regression analyses through adjusting for age and sex.

RESULTS

No difference was detected in age, sex, smoking status, profession, education level, marital status, alcohol consumption, or using liver-protecting drugs (p > 0.05). Compared with non-ADLI group, GG genotype and G allele were significantly higher in ADLI group (p < 0.05).

CONCLUSION

Our results indicated that CYP2S1 rs338599 polymorphism conferred reduced risk to ADLI. The tuberculosis patients who had GG genotype or G allele were not susceptible to ADLI. CYP2S1 rs338599 polymorphism may be a novel marker for ADLI risk prediction.